Parkinson disease (PD) is a complex disorder with motor, cognitive, and behavioral dysfunctions that change over time. The methods to study PD have also become ijiore complex, including the study of biomarkers, genetics, and postmortem-dependent neurobiology. Thus, a successful Clinical Core must not only characterize the motor, cognitive, and behavioral function in PD subjects over time, but also concomitantly carefully collect biological fluids during that same timeframe, and obtain postmortem material from these well-characterized subjects. The primary goal of the Clinical Core will be to support the Pacific Northwest Udall Center (PANUC) Projects through longitudinal characterization of PD subjects and generation of biologic samples from these subjects. To accomplish this goal two PD subject samples will be established. The "community" sample (CS) will be a larger sample evaluated by Clinical Core study personnel at local movement disorder clinics, or at their homes, twice during the five year Center funding cycle. This sample will generate the large number of blood samples, with clinical characterization, needed for the biomarker and genetic projects. The CS will also be the source of subjects for the "annual" sample (AS). The AS will be a smaller subject sample selected for clinical characteristics on screening (e.g., cognitive subtypes such as cognitive impairment without dementia). AS subjects will be evaluated annually at the study site and will have more detailed clinical characterization. In addition, these subjects will be recruited for lumbar punctures to supply CSF for biomarker studies, and for autopsy. The Clinical Core will, therefore, develop PD subject samples with detailed clinical characterization, and collect biological samples from the subjects, to support Projects 2 and 3 in PANUC as well as closely aligned studies. Clinical data, DNA, and biofluids from control individuals will be obtained through the same protocols at each sites'respective NIH-funded AD Center. These unique and integrated data and samples from longitudinally evaluated PD subjects will be an invaluable resource for future studies by PANUC investigators, and for other investigators from within and outside the participating institutions.
Parkinson's Disease (PD) is a progressive disease of the brain that currently affects over a million Americans. We now know that in addition to the movement problems commonly associated with PD this disease eventually also affects a persons thinking or cognitive abilities. This study will improve our understanding of what causes PD-associated cognitive decline, with the long-term objective of developing better treatments for this disabling facet of PD.
|Chahine, Lama M; Stern, Matthew B; Chen-Plotkin, Alice (2014) Blood-based biomarkers for Parkinson's disease. Parkinsonism Relat Disord 20 Suppl 1:S99-103|
|Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405-12|
|Shi, Min; Liu, Changqin; Cook, Travis J et al. (2014) Plasma exosomal ?-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 128:639-50|
|Burdick, Daniel J; Cholerton, Brenna; Watson, G S et al. (2014) People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Mov Disord 29:1258-64|
|Gallardo, Christian M; Darvas, Martin; Oviatt, Mia et al. (2014) Dopamine receptor 1 neurons in the dorsal striatum regulate food anticipatory circadian activity rhythms in mice. Elife 3:e03781|
|Halliday, Glenda M; Leverenz, James B; Schneider, Jay S et al. (2014) The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 29:634-50|
|Darvas, Martin; Henschen, Charles W; Palmiter, Richard D (2014) Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease. Neurobiol Dis 65:112-23|
|Cohen, Rajal G; Klein, Krystal A; Nomura, Mariko et al. (2014) Inhibition, executive function, and freezing of gait. J Parkinsons Dis 4:111-22|
|Nuytemans, Karen; Inchausti, Vanessa; Beecham, Gary W et al. (2014) Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease. Mov Disord 29:827-30|
|Stewart, Tessandra; Sui, Yu-Ting; Gonzalez-Cuyar, Luis F et al. (2014) Cheek cell-derived *-synuclein and DJ-1 do not differentiate Parkinson's disease from control. Neurobiol Aging 35:418-20|
Showing the most recent 10 out of 81 publications